10x Genomics, Inc. (TXG) fair value analysis
Nasdaq · Updated 2026-10-19
TXG price how computed
Valuation status
No fair-value estimate yetTXG has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for TXG yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $69.86
- Sector
- Healthcare
- 12-month range
- $12.44–$97.74
- Market cap
- $8.4B
- From 52-week high
- -28.5%
- Shares outstanding
- 120M
- Rank in Healthcare by quality score
- #45 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
10x Genomics, Inc. is a life sciences company that develops and sells instruments and consumables for analyzing genes and proteins at the single-cell level, enabling researchers to study biological systems with greater precision. The company operates globally, serving research institutions, hospitals, and pharmaceutical companies across multiple continents.
TXG currently ranks #45 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $8.4B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $617M
- Net margin
- -12.2%
- EPS (TTM)
- $-0.02
- Gross margin
- 74.5%
- Debt / equity
- 0.10
- Revenue growth (3-yr avg)
- -0.6%
- Shares outstanding
- 120M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 43 · neutral
- 50-day average
- $70.90
- 200-day average
- $37.81
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05 (post-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+39.1%)
2026-03 ▲ beat (+216.7%)
2025-12 ▲ beat (+275.0%)
2025-09 ▲ beat (+71.4%)
2025-06 ▲ beat (+180.0%)
2025-03 ▲ beat (+65.5%)
2024-12 ▼ miss (-27.3%)
2024-09 ▲ beat (+92.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 12 hold · 0 sell (19 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $77
- Target vs last price
- +10.2%
What our data shows for TXG
- Shares are trading in the upper third of their 12-month price range of $12.44–$97.74.
- The 14-day relative strength index sits at a neutral 43.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- TXG's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent TXG news
TickrTrends' derived news-sentiment signal for TXG is currently leaning positive, computed from recent coverage.
- 10x Genomics Inc (TXG) Shares Surge 5.3% -- What GF Score of 57 Tells Investors (gurufocus.com, 2026-10-02)
- 10x Genomics Inc (TXG) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 60/100 (gurufocus.com, 2026-09-28)
- Director Shehnaaz Suliman Sells 5,723 Shares of 10x Genomics Inc (TXG) (gurufocus.com, 2026-09-25)
What people are saying
Follow the TXG conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for TXG show a shift in trend momentum this week. The 50/200-day trend state has moved from an uptrend to a mixed state, indicating less directional clarity in recent price action. The current valuation verdict remains awaiting full valuation.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for TXG showed material improvement this week. The quality grade advanced from B to A, while the relative strength index zone moved from overbought to neutral conditions. The current valuation verdict remains awaiting full valuation.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — TickrTrends' derived indicators for TXG show a shift this week as the RSI zone moved from neutral to overbought. The stock currently awaits a full valuation assessment. This momentum indicator change reflects increased buying pressure in the healthcare sector name over the recent period.
Frequently asked questions
Is TXG stock undervalued?
TickrTrends has no fair-value estimate for TXG yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is TXG's TickrTrends verdict?
TXG is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does TXG compare to other Healthcare stocks?
TXG ranks #45 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is TXG overbought or oversold?
TXG's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does TXG report earnings next?
TXG's next earnings report is scheduled for 2026-11-05 (post-market), per the published earnings calendar.
Does TXG usually beat earnings estimates?
Over its last 8 reported quarters TXG beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about TXG?
Of 19 analysts covering TXG, 7 rate it a buy, 12 a hold and 0 a sell - hold-leaning, with a consensus price target of $77 (+10.2% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.